modality-agnostic delivery

FlowPoint Bio is developing high-viability nuclear delivery for next-generation cell and gene therapies. Its NEST platform delivers large genetic payloads directly into the nucleus without viral vectors or electroporation, using continuous microfluidic flow and silicon nanolancets that pierce plasma and nuclear membranes, achieving >90% viability and payloads exceeding 10kB.

Read more

direct nuclear deliveryhigh-viability transfectionlarge payload delivery (>10kB)microfluidic deliveryscale from lab bench to bioreactor